Humulin R U-500 KwikPen Now Available

Humulin R U-500 KwikPen Now Available

Eli Lilly announced the launch of Humulin R U-500 KwikPen (insulin human injection), a prefilled device containing a highly concentrated formulation of insulin.

CDC Says Prioritize Use of Antibiotic for Syphilis After Shortage Announced

CDC Says Prioritize Use of Antibiotic for Syphilis After Shortage Announced

All products are currently on backorder, which is expected to resolve by July 2016.

FDA Approves First Commercial Zika Test

FDA Approves First Commercial Zika Test

Quest will charge $120 for patients who don't have health insurance

These Foods Increase Microbial Diversity in the Gut

These Foods Increase Microbial Diversity in the Gut

Findings from two separate studies

Guidelines for Atopic Dermatitis Management Developed

Guidelines for Atopic Dermatitis Management Developed

Current treatment strategies include use of drug therapy, skin care, avoiding exacerbating factors

Gadavist Approved for Use with MRA of the Supra-Aortic Arteries

Gadavist Approved for Use with MRA of the Supra-Aortic Arteries

Bayer announced that the Food and Drug Administration (FDA) has approved Gadavist (gadobutrol) injection for use with magnetic resonance angiography (MRA) to evaluate known or suspected supra-aortic or renal artery disease in adult and pediatric patients, including term neonates.

FDA to Discuss Mandatory Safety Training for Opioid Prescribers

FDA to Discuss Mandatory Safety Training for Opioid Prescribers

Experts from the FDA Drug Safety and Risk Management Advisory Committee and the Anesthetic and Analgesic Drug Products Advisory Committee will meet in May.

FDA Approves New Pediatric Use for ProAir RespiClick

FDA Approves New Pediatric Use for ProAir RespiClick

Teva announced that the FDA has approved ProAir RespiClick (albuterol sulfate) inhalation powder for the treatment or prevention of bronchospasm in children aged 4-11 years with reversible obstructive airway disease and for the prevention of exercise-induced bronchospasm.

Oral Postpartum Hemorrhage Treatment Now Available

Oral Postpartum Hemorrhage Treatment Now Available

Lupin Pharmaceuticals has announced the re-introduction of Methergine (methylergonovine maleate) Oral Tablets 0.2mg for the prevention and management of postpartum hemorrhage (PPH).

FDA Advisory Committee Votes Against DMD Drug Approval

FDA Advisory Committee Votes Against DMD Drug Approval

A majority of The Food and Drug Administration's (FDA) Advisory Committee voted against recommending eteplirsen, which in its New Drug Application (NDA), proposes to become the first drug to treat Duchenne muscular dystrophy.

Pain Drug Xtampza ER Gets Approval from FDA

Pain Drug Xtampza ER Gets Approval from FDA

Collegium announced that the Food and Drug Administration (FDA) has approved Xtampza ER (oxycodone) extended-release (ER) capsules for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment, and for which alternative treatment options are inadequate

Review Compares Intranasal Steroid Preparations for Chronic Rhinosinusitis

Review Compares Intranasal Steroid Preparations for Chronic Rhinosinusitis

For patients with chronic rhinosinusitis, study authors found insufficient data to suggest that one type of intranasal steroid was more effective than another.

Can SGLT-2 Inhibitors Delay Diabetes in At-Risk Patients?

Can SGLT-2 Inhibitors Delay Diabetes in At-Risk Patients?

Researchers have found no evidence in current literature as to whether sodium-glucose contransporter-2 (SGLT-2) inhibitors are able to prevent or delay the development of type 2 diabetes mellitus (T2DM) and its complications in patients at risk for developing T2DM.

Hearing Impairment Risks Increase With Type 2 Diabetes

Hearing Impairment Risks Increase With Type 2 Diabetes

Type 2 diabetes may raise the risk of hearing loss, according to a review published recently in Current Diabetes Reports.

Ilaris Granted 3 Breakthrough Designations for Rare Types of Periodic Fever Syndromes

Ilaris Granted 3 Breakthrough Designations for Rare Types of Periodic Fever Syndromes

Novartis announced that the Food and Drug Administration (FDA) have granted Ilaris (canakinumab) three Breakthrough Therapy Designations, to treat three types of rare Periodic Fever Syndromes (also known as Hereditary Periodic Fevers).

Promising Results in Phase 3 Trials for Nebulized Glycopyrrolate in COPD

Promising Results in Phase 3 Trials for Nebulized Glycopyrrolate in COPD

Sunovion Pharmaceuticals announced positive data from its Phase 3 study of SUN-101 (glycopyrrolate), to treat people with moderate-to-very severe chronic obstructive pulmonary disease (COPD).

Asthma in the ER: Single-Dose Dexamethasone vs. 5-Day Course of Prednisone

Asthma in the ER: Single-Dose Dexamethasone vs. 5-Day Course of Prednisone

The rate of relapse was found to be only slightly higher in asthma patients treated with a single dose of oral dexamethasone in the ER versus a 5-day course of prednisone

Acid-Reducing Drug Prescribing Still Common for Infants Despite Warnings

Acid-Reducing Drug Prescribing Still Common for Infants Despite Warnings

Research has shown that histamine-2 receptor antagonists (H2RAs) and proton-pump inhibitors (PPIs) are often prescribed to extremely preterm neonates and those with congenital anomalies despite the growing safety concerns.

FDA Needs More Data for Antipsychotic Pill with Adherence Sensor

FDA Needs More Data for Antipsychotic Pill with Adherence Sensor

Otsuka and Proteus announced that the Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL) for their drug/device product, which combines Abilify (aripiprazole) with an ingestible sensor embedded in a single tablet.

Triferic Powder Packets Approved for Iron Replacement in Hemodialysis Patients

Triferic Powder Packets Approved for Iron Replacement in Hemodialysis Patients

Rockwell Medical announced that the Food and Drug Administration (FDA) has approved Triferic (ferric pyrophosphate citrate) powder packet for the replacement of iron to maintain hemoglobin in adult patients with hemodialysis-dependent chronic kidney disease (CKD).

FDA Approves Oral Suspension Formulation for HT-1 Treatment

FDA Approves Oral Suspension Formulation for HT-1 Treatment

The Food and Drug Administration (FDA) has approved Orfadin (nitisinone; Sobi) Oral Suspension for the treatment of hereditary tyrosinemia type 1 (HT-1) in combination with dietary restriction of tyrosine and phenylalanine.

CDC Warns of Counterfeit Opioid Poisoning Outbreak

CDC Warns of Counterfeit Opioid Poisoning Outbreak

The Centers for Disease Control and Prevention (CDC) reported on a case where two patients presented to the emergency department in Contra Costa County, CA, suffering from a counterfeit Norco (hydrocodone, acetaminophen) intoxication.

AM vs. PM Vaccination May Impact Antibody Response

AM vs. PM Vaccination May Impact Antibody Response

Vaccinations in the morning may result in a more enhanced antibody response in older adults, a new study published in Vaccine has found.

Adding These Nutraceuticals May Improve Antidepressant Therapy

Adding These Nutraceuticals May Improve Antidepressant Therapy

Findings from a new study published in The American Journal of Psychiatry suggest that some nutritional supplements can enhance the efficacy of antidepressants for patients with depression.

Visible Glass Particulate Discovered in Anesthesia Medication

Visible Glass Particulate Discovered in Anesthesia Medication

Fresenius Kabi announced a voluntary recall of a single lot of Sensorcaine-MPF (bupivacaine HCl) Injection due to visible particulate matter that was observed during inspection of reserve samples.

FDA Issues Advisory for Antifungal After Reports of Miscarriage Risk

FDA Issues Advisory for Antifungal After Reports of Miscarriage Risk

The Food and Drug Administration (FDA) is advising caution when prescribing oral fluconazole (Diflucan) in pregnancy after evaluating data from a Danish study that indicated a possible increased risk of miscarriage when used to treat yeast infections.

POGO Glucose Monitoring System Simplifies Testing for Patients

POGO Glucose Monitoring System Simplifies Testing for Patients

Intuity Medical announced that the Food and Drug Administration (FDA) has cleared the POGO Automatic Blood Glucose Monitoring System, the first blood glucose meter and multi-test cartridge to provide automatic testing with lancing, blood collection, and analysis.

Bevespi Aerosphere Approved for COPD

Bevespi Aerosphere Approved for COPD

The FDA has approved Bevespi Aerosphere (glycopyrrolate/formoterol fumarate) inhalation aerosol for the long-term, maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and/or emphysema.

Cabometyx Approved for Advanced Renal Cell Carcinoma

Cabometyx Approved for Advanced Renal Cell Carcinoma

The Food and Drug Administration (FDA) has approved Cabometyx (cabozantinib; Exelixis) for the treatment of advanced renal cell carcinoma in patients who have received prior anti-angiogenic therapy.

Which Drugs Are Most Associated With Stevens-Johnson Syndrome?

Which Drugs Are Most Associated With Stevens-Johnson Syndrome?

New findings from a study published in the American Journal of Medicine may help clinicians identify high-risk drugs and high-risk patients linked to the development of Stevens-Johnson syndrome (SJS)/toxic epidermal necrolysis (TEN) in order to reduce its incidence.

Smoking Cessation Drugs Evaluated for Neuropsychiatric Safety

Smoking Cessation Drugs Evaluated for Neuropsychiatric Safety

New trial data may alleviate some concerns regarding the smoking cessation medications varenline, bupropion and nicotine patches and the risk of neuropsych events.

Treating Infective Endocarditis: Is One Antibiotic Regimen Better than Another?

Treating Infective Endocarditis: Is One Antibiotic Regimen Better than Another?

Recommended antibiotic regimes to treat infective endocarditis vary between guidelines. In a new review of clinical benefits and harms among different antibiotics, no clear evidence was found to inform which regimen should be used in preference to another, leading to a call for further randomized controlled trials to be conducted.

FDA Grants Opdivo New Breakthrough Therapy Status

FDA Grants Opdivo New Breakthrough Therapy Status

Bristol-Myers Squibb announced that the Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation to Opdivo (nivolumab), to potentially treat recurrent or metastic squamous cell carcinoma of the head and neck (SCCHN) after platinum based therapy.

FDA Expands Use of Viekira Pak in HCV Patients

FDA Expands Use of Viekira Pak in HCV Patients

AbbVie announced that the FDA has approved a sNDA for the use of Viekira Pak (ombitasvir, paritaprevir, ritonavir tablets; dasabuvir tablets) without ribavirin in patients with genotype 1b (GT1b) chronic HCV infection and compensated cirrhosis.

Androxy Available Again for Testosterone Replacement

Androxy Available Again for Testosterone Replacement

Upsher-Smith announced that Androxy (fluoxymesterone) tablets are now available.

Hundreds of Meds Recalled Over Product Sterility Concerns

Hundreds of Meds Recalled Over Product Sterility Concerns

Concerns over lack of sterility and quality issues has prompted a recall of all sterile products aseptically compounded and packaged by Pharmakon Pharmaceuticals.

Do Omega-3s Improve Cognition in Alzheimer's Disease?

Do Omega-3s Improve Cognition in Alzheimer's Disease?

A meta-analysis of three randomized controlled trials found no convincing evidence that omega-3 polyunsaturated fatty acids (PUFAs) when compared to placebo, were effective in the treatment of mild to moderate Alzheimer's disease.

FDA Moves to Ban Controversial Therapy

FDA Moves to Ban Controversial Therapy

The Food and Drug Administration (FDA) has announced a proposal to ban electrical stimulation devices (ESDs) used for self-injurious or aggressive behavior.

Risperidone in Autism Spectrum Disorder: A Weighty Issue

Risperidone in Autism Spectrum Disorder: A Weighty Issue

For children with autistic disorder, treatment with risperidone over a 6 month period was associated with an average weight gain of 5.4±3.4kg (P=.0001), those are the findings of a new study published in the Journal of the American Academy of Child and Adolescent Psychiatry.

Can Watercress Combat the Toxic Effects of Smoking?

Can Watercress Combat the Toxic Effects of Smoking?

Watercress extract was shown to reduce the activation of carcinogens caused by smoking by 7.7%, in a new randomized trial.

Efficacy of Fingolimod vs. Rituximab Compared in Patients with Highly Active MS

Efficacy of Fingolimod vs. Rituximab Compared in Patients with Highly Active MS

For relapsing-remitting multiple sclerosis patients infected with JC virus and taking natalizumab, switching treatment to rituximab was associated with better outcomes than switching to fingolimod.

Study Tests β Blocker Efficacy in HFrEF Patients Across Age and Sex

Study Tests β Blocker Efficacy in HFrEF Patients Across Age and Sex

A pooled data analysis of 11 randomized controlled trials has found that β blockers reduce the risk of death and hospitalization in patients with reduced ejection fraction (HFrEF) and sinus rhythm, regardless of age or sex.

Are Antibiotics Useful in the Treatment of Peptic Ulcer?

Are Antibiotics Useful in the Treatment of Peptic Ulcer?

In this updated review, published online in the Cochrane Library, researchers aimed to assess the magnitude of effect H. pylori eradication therapy has on H. pylori-positive patients with peptic ulcer disease.

Study Shows It May Be Possible to Clear HCV in 6 Weeks with This Regimen

Study Shows It May Be Possible to Clear HCV in 6 Weeks with This Regimen

Treating acute hepatitis C patients with a regimen of sofosbuvir and ledipasvir for just 6 weeks - instead of the usual 12-weeks - was found to achieve 100% sustained virologic response (SVR) and undetectable Hep C at a Week 12 follow up.

Nplate Demonstrates Efficacy in Pediatric ITP

Nplate Demonstrates Efficacy in Pediatric ITP

Amgen announced published results from a Phase 3 study of Nplate (romiplostim) for the treatment of symptomatic immune thrombocytopenia (ITP) in children. Study data were published in The Lancet.

Consider This Antidepressant as First-Line for Obese, Overweight Patients, Says Study

Consider This Antidepressant as First-Line for Obese, Overweight Patients, Says Study

The antidepressant bupropion was associated with the least weight gain in patients when compared to other second-generation antidepressants.

Xylitol-Based Nasal Care Products Available OTC

Xylitol-Based Nasal Care Products Available OTC

Xlear have announced that their line of xylitol-based products for adults with upper respiratory problems will be available at 1,300 Target stores nationwide.

New OTC Muscle Pain Relief Patches Now Available

New OTC Muscle Pain Relief Patches Now Available

Zim's Max has announced the launch of new lidocaine and menthol pain relieving patches, Zim's Max-Freeze Patches.

Safety and Efficacy of Type 2 Diabetes Meds Compared in New Review

Safety and Efficacy of Type 2 Diabetes Meds Compared in New Review

A review of the latest evidence regarding type 2 diabetes treatment, supports current guidelines which recommend metformin as a first-line therapy.

Updated Guidelines Provide New Evidence for the Use of Botulinum Neurotoxin to Treat Multiple Conditions

Updated Guidelines Provide New Evidence for the Use of Botulinum Neurotoxin to Treat Multiple Conditions

Based on new research the American Academy of Neurology (AAN) has updated its 2008 guidelines on the uses of botulinum neurotoxin for the treatment of spasticity, cervical dystonia, blepharospasm and migraine headache.

Zembrace SymTouch Available for Acute Migraine Episodes

Zembrace SymTouch Available for Acute Migraine Episodes

Promius Pharma announced that Zembrace SymTouch, indicated to treat acute migraine headaches with or without aura in adults, is now commercially available in the U.S.

Novel Chronic Idiopathic Constipation Drug Under FDA Review

Novel Chronic Idiopathic Constipation Drug Under FDA Review

The Food and Drug Administration (FDA) has accepted for review the New Drug Application (NDA) for plecanatide (Synergy) for the treatment of chronic idiopathic constipation (CIC).

New Ready-to-Use Vancomycin Injection Launched

New Ready-to-Use Vancomycin Injection Launched

Baxter has launched ready-to-use Vancomycin Injection in 0.9% Sodium Chloride (Normal Saline) in 500mg, 750mg and 1g presentations.

First Long-Acting Buprenorphine Implant Shows Promise for Opioid Addiction

First Long-Acting Buprenorphine Implant Shows Promise for Opioid Addiction

Braeburn Pharmaceuticals announced positive data from the Phase 3 study of Probuphine (buprenorphine subdermal implant) for the long-term maintenance treatment of opioid addiction. Findings were presented at the 47th Annual American Society of Addiction Medicine (ASAM) Conference.

Extended-Release Liquid Amphetamine for ADHD Now Available

Extended-Release Liquid Amphetamine for ADHD Now Available

Tris Pharma has announced the launch of Dyanavel XR (amphetamine), the first extended-release liquid amphetamine for the treatment of attention deficit hyperactivity disorder (ADHD) in children 6 years and older.

Consider Alternatives to Anticholinergic Meds in Older Patients, Say Researchers

Consider Alternatives to Anticholinergic Meds in Older Patients, Say Researchers

Older patients taking anticholinergic (AC) medication scored significantly lower on three separate brain atrophy and dysfunction tests compared to matched controls who took no AC medication.

New Formulation of Vyvanse Submitted to FDA for Review

New Formulation of Vyvanse Submitted to FDA for Review

Shire announced that it has submitted to the Food and Drug Administration (FDA) a New Drug Application (NDA) for a new, alternate formulation of Vyvanse (lisdexamfetamine dimesylate) as a chewable tablet for patients who may have difficulty swallowing or opening a capsule.

FDA Withdraws Indications for Two Cholesterol Medications

FDA Withdraws Indications for Two Cholesterol Medications

The Food and Drug Administration (FDA) is withdrawing approval of the indications for niacin extended-release (ER) tablets and fenofibric acid delayed-release (DR) capsules related to the coadministration of these agents with statins.

MI Patients Less Likely to Receive Antidepressant Tx, Says Study

MI Patients Less Likely to Receive Antidepressant Tx, Says Study

Patients with a first myocardial infarction frequently report symptoms of depression but are less likely to receive treatment with antidepressants, compared to those who have not had a heart attack.

FDA Grants Keytruda Fourth Breakthrough Therapy Status

FDA Grants Keytruda Fourth Breakthrough Therapy Status

The FDA has granted Keytruda (pembrolizumab) its fourth Breakthrough Therapy designation for the treatment of patients with relapsed or refractory classical Hodgkin lymphoma (cHL).

FDA Approves Treatment for Squamous Cell Carcinoma of the Lung

FDA Approves Treatment for Squamous Cell Carcinoma of the Lung

The Food and Drug Administration (FDA) has approved a supplemental New Drug Application (sNDA) for Gilotrif (afatinib; Boehringer Ingelheim).

Skip the Salt, Lose the Headache?

Skip the Salt, Lose the Headache?

For older patients, a reduction in sodium, which is recommended for blood pressure control, may also help reduce the occurrence of headaches.

Pan-Genotypic HCV Regimen Shows Promise in Trial

Pan-Genotypic HCV Regimen Shows Promise in Trial

AbbVie announced positive results from the ongoing MAGELLAN-1 study, evaluating the efficacy, safety, and pharmacokinetics of ABT-493 and ABT-530, with and without RBV, for the treatment of genotype 1 (GT1) and genotypes 4-6 chronic hepatitis C virus (HCV) infection in non-cirrhotic adults who failed previous therapy with direct-acting antivirals (DAA).

State Gives Green Light to NP, PA Prescribing of Controlled Drugs

State Gives Green Light to NP, PA Prescribing of Controlled Drugs

Florida now joins 48 other states and the District of Columbia in allowing physician assistants (PAs) the ability to prescribe controlled medications, while nurse practitioners are now allowed to prescribe in all 50 states.

Study Skews Perception of Safety for Proton Pump Inhibitors

Study Skews Perception of Safety for Proton Pump Inhibitors

Patients who are taking proton pump inhibitors (PPIs) may be at increased risk for kidney function decline, chronic kidney disease (CKD), and kidney failure.

What Patients Don't Know About Warfarin Could Hurt Them

What Patients Don't Know About Warfarin Could Hurt Them

Patients may not be fully aware of the foods and drugs that can interfere with warfarin treatment and cause serious side effects

Gene Variant Linked to Severe Cutaneous Reactions with Gout Treatment

Gene Variant Linked to Severe Cutaneous Reactions with Gout Treatment

Findings from a new study published in Seminars in Arthritis and Rheumatism show significant racial disparities in the risk of gout patients developing a serious, sometimes fatal adverse reaction to urate-lowering drugs.

HCV Drugs May Reduce Transplant Urgency in Patients with Severe Liver Disease

HCV Drugs May Reduce Transplant Urgency in Patients with Severe Liver Disease

Patients on the liver transplant list with hepatitis C virus (HCV) and decompensated cirrhosis were more likely to be removed from the list or to need a transplant less as a result of direct-acting antiviral therapy, a new study presented at The International Liver Congress 2016 showed.

IDSA/SHEA Release New Antibiotic Stewardship Guidelines

IDSA/SHEA Release New Antibiotic Stewardship Guidelines

The Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA) have released new antibiotic stewardship guidelines.

Zepatier Goes Head-to-Head with Sofosbuvir Regimen in HCV Trial

Zepatier Goes Head-to-Head with Sofosbuvir Regimen in HCV Trial

Merck announced results from the C-EDGE Head-to-Head trial that evaluated the safety and efficacy of Zepatier (elbasvir/grazoprevir) vs. a regimen of sofosbuvir plus peginterferon and ribavirin (pegIFN/RBV) in treatment-naive and pegIFN/RBV treatment-experienced patients with chronic hepatitis C (HCV) genotype (GT) 1 or GT4 infection.

Hospira Recalls Magnesium Sulfate Injection

Hospira Recalls Magnesium Sulfate Injection

Hospira announced a voluntary recall of one lot of 50% Magnesium Sulfate Injection, 10g/20mL (0.5/gmL), 20mL single-dose vials.

Triple-Bead Mixed Amphetamine Salts Shows Promise in ADHD Study

Triple-Bead Mixed Amphetamine Salts Shows Promise in ADHD Study

Shire announced positive topline results from the Phase 3 study, SHP465-305, evaluating SHP465 (triple-bead mixed amphetamine salts - MAS) in children and adolescents aged 6-17 years with Attention-Deficit/Hyperactivity Disorder (ADHD).

Positive Results Announced for Dupilumab in Atopic Dermatitis Studies

Positive Results Announced for Dupilumab in Atopic Dermatitis Studies

Regeneron and Sanofi announced that the two Phase 3 studies, LIBERTY AD SOLO 1 and SOLO 2, evaluating dupilumab for the treatment of adults with inadequately controlled moderate-to-severe atopic dermatitis (AD), met their primary endpoints.

Does Testosterone Tx Reduce Hospital Readmission in Men with Low Testosterone?

Does Testosterone Tx Reduce Hospital Readmission in Men with Low Testosterone?

Older men on testosterone therapy were less likely to experience complications requiring hospital readmission within 1 month of discharge than men not using testosterone therapy, according to a study published in Mayo Clinical Proceedings.

FDA to Review Remoxy NDA for Pain Management

FDA to Review Remoxy NDA for Pain Management

Durect and its licensee, Pain Therapeutics, announced that the Food and Drug Administration (FDA) has accepted for review the New Drug Application (NDA) for Remoxy (extended-release oxycodone).

Orphan Drug Status Granted to Inhaled Antimicrobial Agent Mul-1867

Orphan Drug Status Granted to Inhaled Antimicrobial Agent Mul-1867

The FDA has granted Orphan Drug designation to Mul-1867 (TGV-Inhalonix) for the treatment of antibiotic-resistant bacterial lung infections in patients with cystic fibrosis.

Oska Pulse Wearable Pain Relief Device Now Available

Oska Pulse Wearable Pain Relief Device Now Available

Oska Wellness announced the launch of Oska Pulse, a small wearable pain relief device to help reduce muscle stiffness, temporarily relieve minor pain, and increase mobility in patients with chronic pain.

BromSite Approved for Ocular Inflammation, Pain in Cataract Surgery

BromSite Approved for Ocular Inflammation, Pain in Cataract Surgery

The Food and Drug Administration (FDA) has approved a New Drug Application (NDA) for BromSite (bromfenac ophthalmic solution; InSite Vision) for the treatment of postoperative inflammation and prevention of ocular pain in patients undergoing cataract surgery.

REMS Requirement Removed for Gout Drug

REMS Requirement Removed for Gout Drug

The Food and Drug Administration (FDA) has approved the supplemental Biologics License Application (sBLA) for Krystexxa (pegloticase; Horizon) Injection.

OTC Antihistamine May Help Reverse Vision Damage in MS Patients

OTC Antihistamine May Help Reverse Vision Damage in MS Patients

Clemastine fumarate, an over-the-counter (OTC) antihistamine, was found to partially reverse vision damage in patients with multiple sclerosis (MS), according to a preliminary study that will be presented at the AAN 68th Annual Meeting.

Common Painkiller May Inhibit Brain's Error Detection Ability

Common Painkiller May Inhibit Brain's Error Detection Ability

Acetaminophen, a common analgesic, may be blocking the brain's ability to detect errors, according to a new study published in Social Cognitive and Affective Neuroscience.

Reformulated Metronidazole Granted Orphan Drug for CDI in Children

Reformulated Metronidazole Granted Orphan Drug for CDI in Children

Appili Therapeutics announced that the Food and Drug Administration (FDA) has granted Orphan Drug designation for ATI-1501 (metronidazole) for the potential treatment of Clostridium difficile infection (CDI) in children.

Is Type 2 Diabetes a Major Risk Factor for Chronic Liver Disease?

Is Type 2 Diabetes a Major Risk Factor for Chronic Liver Disease?

The majority of liver disease cases in people with type 2 diabetes are not alcohol-related, according to the findings of a new study which examined hospital and death records in Scotland over a 10-year period.

Does Early PTSD Treatment Benefit Long-Term Outcomes?

Does Early PTSD Treatment Benefit Long-Term Outcomes?

Although the majority of patients with post-traumatic stress disorder (PTSD) recover after early treatment, many others still suffer for years after a traumatic event despite early clinical interventions, a study published in The Journal of Clinical Psychiatry has shown.

Underutilization of Breast Cancer Tx in Older Black Women, Study Reveals

Underutilization of Breast Cancer Tx in Older Black Women, Study Reveals

Researchers from the University of North Carolina at Chapel Hill reported low rates of targeted breast cancer treatments among older women with early-stage breast cancer, especially older black women

Three Undeclared Drugs Found in Weight Loss Capsules

Three Undeclared Drugs Found in Weight Loss Capsules

Super Herbs announced a voluntary recall of its Super Herbs light green and dark green capsules after FDA laboratory testing found them to contain sibutramine, desmethylsibutramine, and/or phenolphthalein.

Discovery of New TB Biomarkers May Lead to More Effective Vaccine

Discovery of New TB Biomarkers May Lead to More Effective Vaccine

For the first time, researchers have discovered evidence on how the tuberculosis (TB) vaccine, Bacillus Calmette-Guérin (BCG), may work.

Over 260,000 Continuous Glucose Monitoring System Receivers Recalled

Over 260,000 Continuous Glucose Monitoring System Receivers Recalled

Dexcom announced a recall of the Continuous Glucose Monitoring Systems due to the possibility of the audible alarm not activating in the receiver piece when hypoglycemia or hyperglycemia is detected.

Palatable CDI Tx for Children Designated Orphan Drug Status

Palatable CDI Tx for Children Designated Orphan Drug Status

Appili Therapeutics announced that the Food and Drug Administration (FDA) has granted Orphan Drug designation for ATI-1501 (metronidazole) for the potential treatment of Clostridium difficile infection (CDI) in children.

FDA Granted Priority Review for Atezolizumab BLA in NSCLC Indication

FDA Granted Priority Review for Atezolizumab BLA in NSCLC Indication

Genentech announced that the Food and Drug Administration (FDA) has accepted and granted Priority Review to the Biologics License Application (BLA) for atezolizumab (anti-PDL1; MPDL3280A

'Breakthrough' CLL Drug Gets FDA Approval

'Breakthrough' CLL Drug Gets FDA Approval

The Food and Drug Administration (FDA) has approved Venclexta (venetoclax; AbbVie and Genentech) for the treatment of patients with chronic lymphocytic leukemia (CLL) who have a 17p deletion and who have been treated with at least one prior therapy.

Prescribing These Drugs After Vascular Surgery May Extend Survival

Prescribing These Drugs After Vascular Surgery May Extend Survival

Initiating antiplatelets and statins after surgery can significantly prolong some patients' lives even if they do not have high cholesterol, a new review published in the Journal of Vascular Surgery has shown.

Potential Tx for CRE Infections Fast Tracked by the FDA

Potential Tx for CRE Infections Fast Tracked by the FDA

The FDA has granted Fast Track designation to Carbavance (meropenem-vaborbactam; The Medicines Company) for the treatment of complicated urinary tract infections (cUTI).

Continuing Drug Therapy May Delay Relapse in Body Dysmorphic Disorder Patients

Continuing Drug Therapy May Delay Relapse in Body Dysmorphic Disorder Patients

A study published in the American Journal of Psychiatry has shown that people with body dysmorphic disorder (BDD) progress better and are less likely to relapse when given long-term medication.

FDA Revises Warnings for Metformin-Containing Drugs

FDA Revises Warnings for Metformin-Containing Drugs

The Food and Drug Administration (FDA) announced it is requiring labeling changes to medications containing metformin to expand its use in certain patients with reduced renal function.

Study Highlights Possible Warfarin, Ezetimibe Drug Interaction

Study Highlights Possible Warfarin, Ezetimibe Drug Interaction

Ezetimibe may enhance and stabilize the effects of warfarin especially in patients taking statins, a new study published in Heart & Vessels has reported.

Blood Test May Help Identify COPD Patients Who Benefit from Addition of ICS

Blood Test May Help Identify COPD Patients Who Benefit from Addition of ICS

Boehringer Ingelheim announced new data showing that the level of eosinophils can help identify patients with chronic obstructive pulmonary disease (COPD) who may and may not benefit from adding inhaled corticosteroid (ICS) treatment.

HPV Vaccine May Not Be as Effective in Kidney Transplant Patients

HPV Vaccine May Not Be as Effective in Kidney Transplant Patients

Administration of the human papillomavirus (HPV) vaccine led to sustained immune response in girls and young women with chronic kidney disease (CKD) and in those on dialysis but led to an inadequate response in those with a kidney transplant.

Dyslipidemia Drug Gets New Contraindication, Warning

Dyslipidemia Drug Gets New Contraindication, Warning

The Food and Drug Administration (FDA) has approved a supplemental New Drug Application (sNDA) for Lopid (gemfibrozil; Pfizer) tablets to include new revisions to the prescribing information.

Zonegran Labeling Updated with New Warning

Zonegran Labeling Updated with New Warning

The Food and Drug Administration (FDA) has approved the supplemental New Drug Application (sNDA) for Zonegran (zonisamide, Concordia) capsules to include a new warning in the prescribing information.

Sign Up for Free e-newsletters